Skip to main content Accessibility help
×
Home
  • Print publication year: 2018
  • Online publication date: February 2018

13 - Developmental Pharmacology

from Section 2 - Newborn and Infant Anesthesia
1.Crawford, J, Terry, M, Rourke, G. Simplification of drug dosage calculation by application of the surface area principle. Pediatrics. 1950;5:783–90.
2.Holliday, M, Segar, W. The maintenance need for water in parenteral fluid therapy. Pediatrics. 1957;19:823–32.
3.Anderson, B, Holford, N. Tips and traps analyzing pediatric PK data. Pediatric Anesthesia. 2011;21:222–37.
4.Robiquet, T. Rapport sur un memoire adresse a l’Academie royale de medecine par MM Sarrus et Rameaux. Bull Acad R Med. 1839;3:1094.
5.Brody, S: Bioenergetics and Growth: With Special Reference to the Efficiency Complex. New York: Reinhold Publishing Corporation; 1945.
6.Rigby-Jones, AE, Sneyd, JR. Pharmacokinetics and pharmacodynamics-is there anything new? Anesthesia. 2012;67:111.
7.Anderson, B, Allegaert, K, Holford, N. Population clinical pharmacology of children: modelling covariate effects. Eur J Pediatr. 2006;165:819–29.
8.Edginton, A. Knowledge-driven approaches for the guidance of first-in-children dosing. Pediatric Anesthesia. 2011;21:206–13.
9.Rhodin, M, Anderson, B, Peters, A, et al. Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr Nephrol. 2009;24:6776.
10.de Wildt, S, Kearns, G, Leeder, J, van den Anker, J. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet. 1999;37:485505.
11.Cella, M, Knibbe, C, Danhof, M, Pascua, OD. What is the right dose for children? Br J Clin Pharmacol. 2010;70:597603.
12.Kearns, G, Abdel-Rahman, S, Alander, S, et al. Developmental pharmacology: drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349:1157–67.
13.Marsh, D, Hatch, D, Fitzgerald, M, et al. Opioid systems and the newborn. Br J Anaes. 1997;79:787–95.
14.Klitzner, T, Friedman, W. A diminished role for the sarcoplasmic reticulum in newborn myocardial contraction: effects of ryanodine. Ped Res. 1989;26:98101.
15.Johnson, T, Rostami-Hodjegan, A. Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice. Paediatr Anesth. 2011;21:291301.
16.Johnson, T, Rostami-Hodjegan, A, Tucker, G. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet. 2006;45:931–56.
17.Keys, T. The History of Surgical Anesthesia. New York: Dover Publications; 1963.
18.Coté, CJ. Pediatric anesthesia. In: Miller, RD, Eriksson, LI, Fleisher, LA, et al., editors. Miller’s Anesthesia, 7th edn. Philadelphia, PA: Churchill Livingstone; 2010.
19.Vlajkovic, G, Sindjelic, R. Emergence delirium in children: many questions, few answers. Anesth Analg. 2007;4:8491.
20.Friedman, W. The intrinsic physiologic properties of the developing heart. Prog Cardiovasc Dis. 1972;15:87111.
21.Blanco, C, Dawes, G, Hanson, M. Carotid baroreceptors in fetal and newborn sheep. Ped Res. 1988;24:342–6.
22.Friedman, W, George, B. Treatment of congestive heart failure by altering loading conditions of the heart. J Ped. 1985;106:697706.
23.Holden, K, Morgan, J, Krauss, A. Incomplete baroreceptor responses in newborn infants. Amer J Perinat. 1985;2:31–4.
24.Gournay, V, Drouin, E, Rozé, J. Development of baroreflex control of heart rate in preterm and full term infants. Arch Dis Child Fetal Neonatal Ed. 2002;86: F151–4.
25.Patton, D, Hanna, B. Postnatal maturation of baroreflex heart rate control in neonatal swine. Can J Cardiol. 1994;10:233–8.
26.Holzman, R, van der Velde, M, Kaus, S, et al. Sevoflurane depresses myocardial contractility less than halothane during induction of anesthesia in children. Anesthesiology. 1996;85:1260–7.
27.Steur, R, Perez, R, De Lange, J. Dosage scheme for propofol in children under 3 years of age. Paediatr Anaesth. 2004;14:462–7.
28.Jacqz-Aigrain, E, Burtin, P. Clinical pharmacokinetics of sedatives in neonates. Clin Pharmacokinet. 1996;31:423–43.
29.Anderson, B, Allegaert, K. The pharmacology of anaesthetics in the neonate. Best Pract Res Clin Anaesth. 2010;24:419–31.
30.Pacifici, G. Clinical pharmacology of midazolam in neonates and children: effect of disease – a review. Int J Pediatr., 2014. doi: 10.1155/2014/309342.
31.de Wildt, S, Kearns, G, Hop, W, et al. Pharmacokinetics and metabolism of intravenous midazolam in preterm infants. Clin Pharmacol Ther. 2001;70:525–31.
32.Burtin, P, Jacqz-Aigrain, E, Girard, P, et al. Population pharmacokinetics of midazolam in neonates. Clin Pharmacol Ther. 1994;56:615–25.
33.Wermeling, D, Miller, J, Archer, S, Manaligod, J, Rudy, A. Bioavailability and pharmacokinetics of lorazaepam after intranasal, intravenous and intramuscular administration. J Clin Pharmacol. 2001;41:1225–31.
34.McDermott, C, Kowalczyk, A, Schnitzler, E, et al. Pharmacokinetics of lorazepam in critically ill neonates with seizures. J Pediatr. 1992;120:479–83.
35.Chrysostomou, C, Zeballos, T. Use of dexmedetomidine in a pediatric heart transplant patient. Pediatr Cardiol. 2005;26:651–4.
36.Finkel, J, Johnson, Y, Quezado, Z. The use of dexmedetomidine to facilitate acute discontinuation of opioids after cardiac transplantation in children. Crit Care Med. 2005;33:2110–12.
37.Ard, J, Doyle, W, Bekker, A. Awake craniotomy with dexmedetomidine in pediatric patients. J Neurosurg Anesth. 2003;15:263–6.
38.Tobias, J, Berkenbosch, J. Sedation during mechanical ventilation in infants and children: dexmedetomidine versus midazolam. J Neurosurg Anesthesiol. 2003;15:263–6.
39.Berkenbosch, J, Tobias, J. Development of bradycardia during sedation with dexmedetomidine in an infant concurrently receiving digoxin. Pediatr Crit Care Med. 2003;4:203–5.
40.Chrysostomou, C, Schulman, S, Castellanos, M, et al. A phase II/III, multicenter, safety, efficacy, and pharmacokinetic study of dexmedetomidine in preterm and term neonates. J Pediatr. 2014;164:276–82.
41.Potts, A, Warman, G, Anderson, B. Dexmedetomidine disposition in children: a population analysis. Ped Anaesth. 2008;18:722–30.
42.Talke, P, Richardson, C, Scheinin, M, Fisher, D. Postoperative pharmacokinetics and sympatholytic effects of dexmedetomidine. Anesth Analg. 1997;85:1136–42.
43.Talke, P, Chen, R, Thomas, B, et al. The hemodynamic and adrenergic effects of perioperative dexmedetomidine infusion after vascular surgery. Anesth Analg. 2000;90:834–9.
44.Hsu, Y, Cortinez, L, Robertson, K, et al. Dexmedetomidine pharmacodynamics: part I. Anesthesiology. 2004;101:1066–76.
45.Cortinez, L, Hsu, Y, Sum-Ping, S, et al. Dexmedetomidine pharmacodynamics: part II. Anesthesiology. 2004;101:1077–83.
46.Petroz, G, Sikich, N, James, M, et al. A phase I, two-center study of the pharmacokinetics and pharmacodynamics of dexmedetomidine in children. Anesthesiology. 2006;105:1098–110.
47.Berkenbosch, J, Wankum, P, Tobias, J. Prospective evaluation of dexmedetomidine for noninvasive procedural sedation in children. Pedatr Crit Care Med. 2005;6:435–9.
48.Bouwmeester, N, van den Anker, J, Hop, W, Anand, K, Tibboel, D. Age- and therapy-related effects on morphine requirements and plasma concentrations of morphine and its metabolites in postoperative infants. Br J Anaesth. 2003;90:642–52.
49.Bouwmeester, N, Anderson, B, Tibboel, D, Holford, N. Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. Br J Anaesth. 2004;92:208–17.
50.Tegeder, I, Lotsch, J, Geisslinger, G. Pharmacokinetics of opioids in liver disease. Clin Pharmacokinetics. 1999;37:1740.
51.Davis, P, Wilson, A, Siewers, R. The effects of cardiopulmonary bypass on remifentanil kinetics in children undergoing atrial septal defect repair. Anesth Analg. 1999;89:904–8.
52.Ross, A, Davis, P, Dear, G, et al. Pharmacokinetics of remifentanil in anesthetized pediatric patients undergoing elective surgery or diagnostic procedures. Anesth Analg. 2001;93:1393–401.
53.Welzing, L, Roth, B. Experience with remifentanil in neonates and infants. Drugs. 2006;66:1339–50.
54.Greeley, W, de Bruijn, N, Davis, D. Sufentanil pharmacokinetics in pediatric cardiovascular patients. Anesth Analg. 1987;66:1067–72.
55.Lundeberg, S, Roelofse, J. Aspects of pharmacokinetics and pharmacodynamics of sufentanil in pediatric practice. Paediatr Anaesth. 2011;21:274–9.
56.Pokela, M, Ryhanen, P, Koivisto, M, Olkkola, K, Saukkonen, A. Alfentanil-induced rigidity in newborn infants. Anesth Analg. 1992;75:252–7.
57.Anderson, B, van Lingen, R, Hansen, T, Lin, Y, Holford, N. Acetaminophen developmental pharmacokinetics in premature neonates and infants: a pooled population analysis. Anesthesiology. 2002;96:1336–45.
58.Allegaert, K, Naulaers, G, Vanhaesebrouck, S, Anderson, B. The paracetamol concentration-effect relation in neonates. Pediatric Anesthesia. 2013;23:4550.
59.Playfor, S, Jenkins, I, Boyles, C, et al. Consensus guidelines for sustained neuromuscular blockade in critically ill children. Pediatr Anesth. 2007;17:881–7.
60.Martin, L, Bratton, S, O’Rourke, P. Clinical uses and controversies of neuromuscular blocking agents in infants and children. Crit Care Med.. 1999;27:1358–68.
61.Martyn, J, White, D, Gronert, G, Jaffe, R, Ward, J. Up-and-down regulation of skeletal muscle acetylcholine receptors. Anesthesiology. 1992;76:822–43.
62.Meakin, G, McKiernan, E, Morris, P, Baker, R. Dose–reponse curves for suxamethonium in neonates, infants and children. Br J Anaesth. 1989;62:655–8.
63.Hospira Inc. Succinylcholine chloride IV injection [Package insert]. Lake Forest, IL, Hospira, Inc, 2005
64.Goudsouzian, N, Ryan, J, Savarese, J. The neuromuscular effects of pancuronium in infants and children. Anesthesiology. 1974;41:95–8.
65.Meretoja, O, Wirtavuori, K, Neuvonen, P. Age-dependence of the dose–response curve of vecuronium in pediatric patients during balanced anesthesia. Anesth Analg. 1988;67:21–6.
66.Fisher, D, Castagnoli, K, Miller, R. Vecuronium kinetics and dynamics in anesthetized infants and children. Clin Pharmacol Ther. 1985;37:402–6.
67.Foldes, F, Nagashima, H, Nguyen, H, et al. The neuromuscular effects of ORG9426 in patients receiving balanced anesthesia. Anesthesiology. 1991;75:191–6.
68.Woelfel, S, Brandom, B, Cook, D, Sarner, J. Effects of bolus administration of ORG-9426 in children during nitrous oxide–halothane anesthesia. Anesthesiology. 1992;76:939–42.